chlorpromazine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
621 50-53-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlorpromazine
  • 2-Chloropromazine
  • chlordelazin
  • chlorderazin
  • thorazine
  • contomin
  • chlorpromazine hydrochloride
  • chlorpromazine HCl
The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
  • Molecular weight: 318.86
  • Formula: C17H19ClN2S
  • CLOGP: 5.50
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.88
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.10 g P
0.30 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 52.37 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 11 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 18, 1957 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 238.96 21.66 81 8334 11975 63468632
Sopor 207.75 21.66 86 8329 22078 63458529
Drug abuse 188.22 21.66 118 8297 72400 63408207
Toxicity to various agents 172.87 21.66 187 8228 247063 63233544
Electrocardiogram QT prolonged 139.82 21.66 91 8324 59439 63421168
Catatonia 133.35 21.66 41 8374 4436 63476171
Overdose 119.16 21.66 108 8307 114970 63365637
Suicide attempt 111.85 21.66 80 8335 60838 63419769
Aggression 97.65 21.66 52 8363 23446 63457161
Intentional self-injury 93.30 21.66 52 8363 25635 63454972
Coma 90.34 21.66 72 8343 64292 63416315
Agitation 86.34 21.66 68 8347 59689 63420918
Mania 73.85 21.66 35 8380 12332 63468275
Intentional overdose 67.80 21.66 65 8350 74087 63406520
Psychotic disorder 66.98 21.66 42 8373 25670 63454937
Mental disorder 64.18 21.66 41 8374 25878 63454729
Poisoning deliberate 61.67 21.66 30 8385 11188 63469419
Tardive dyskinesia 59.93 21.66 27 8388 8475 63472132
Depressed level of consciousness 59.76 21.66 56 8359 62022 63418585
Delusion 59.71 21.66 30 8385 11987 63468620
Sedation 57.84 21.66 45 8370 38764 63441843
Completed suicide 56.13 21.66 82 8333 145591 63335016
Hallucination, auditory 55.01 21.66 29 8386 12795 63467812
Psychomotor hyperactivity 54.10 21.66 27 8388 10636 63469971
Drug interaction 49.83 21.66 100 8315 229031 63251576
Cardiac arrest 49.25 21.66 61 8354 92484 63388123
Stereotypy 46.65 21.66 11 8404 431 63480176
Somnolence 44.98 21.66 83 8332 178602 63302005
Pneumonia aspiration 44.96 21.66 37 8378 34503 63446104
Mutism 44.63 21.66 14 8401 1616 63478991
Wrong patient received product 44.36 21.66 15 8400 2192 63478415
Behaviour disorder 42.53 21.66 16 8399 3183 63477424
Hepatocellular injury 41.33 21.66 32 8383 27349 63453258
Salivary hypersecretion 40.63 21.66 20 8395 7646 63472961
Torsade de pointes 40.38 21.66 24 8391 13327 63467280
Arthralgia 39.87 21.66 13 8402 569697 62910910
Grandiosity 39.84 21.66 9 8406 291 63480316
Miosis 38.43 21.66 19 8396 7334 63473273
Pain 37.94 21.66 26 8389 740602 62740005
Hallucinations, mixed 36.16 21.66 16 8399 4813 63475794
Hypotonia neonatal 35.36 21.66 11 8404 1235 63479372
Disorganised speech 35.20 21.66 11 8404 1254 63479353
Tachycardia 35.03 21.66 59 8356 118097 63362510
Epileptic encephalopathy 34.56 21.66 8 8407 289 63480318
Abnormal behaviour 34.45 21.66 26 8389 21400 63459207
Gaze palsy 33.94 21.66 11 8404 1409 63479198
Eosinophilic myocarditis 33.35 21.66 9 8406 611 63479996
Altered state of consciousness 32.77 21.66 27 8388 25203 63455404
Psychomotor skills impaired 32.05 21.66 12 8403 2356 63478251
Lactate pyruvate ratio increased 30.95 21.66 6 8409 90 63480517
Fatigue 30.73 21.66 44 8371 887984 62592623
Muscle rigidity 30.48 21.66 19 8396 11481 63469126
Pain in extremity 30.45 21.66 4 8411 331482 63149125
Premature delivery 30.44 21.66 28 8387 30253 63450354
Illusion 28.50 21.66 9 8406 1061 63479546
Extrapyramidal disorder 27.97 21.66 19 8396 13265 63467342
Dyspnoea 27.91 21.66 28 8387 661285 62819322
Tremor 27.84 21.66 57 8358 132182 63348425
Confusional state 27.42 21.66 81 8334 236299 63244308
Dysarthria 27.41 21.66 31 8384 42680 63437927
Blood citric acid increased 26.91 21.66 5 8410 59 63480548
Anger 26.67 21.66 18 8397 12438 63468169
Cardio-respiratory arrest 26.38 21.66 36 8379 59923 63420684
Swelling 26.07 21.66 3 8412 275375 63205232
Onychophagia 25.98 21.66 5 8410 72 63480535
Newborn persistent pulmonary hypertension 25.60 21.66 6 8409 229 63480378
Hypothermia 25.26 21.66 18 8397 13563 63467044
Abdominal discomfort 24.86 21.66 6 8409 320879 63159728
Myocarditis 24.72 21.66 16 8399 10309 63470298
Otospondylomegaepiphyseal dysplasia 24.68 21.66 5 8410 95 63480512
Blood creatine phosphokinase increased 24.67 21.66 25 8390 30405 63450202
Schizoaffective disorder 24.11 21.66 11 8404 3551 63477056
Drug intolerance 23.47 21.66 6 8409 308655 63171952
Drug use disorder 23.46 21.66 12 8403 4972 63475635
Hepatic cytolysis 23.23 21.66 18 8397 15389 63465218
Alopecia 23.05 21.66 8 8407 337528 63143079
Mitochondrial enzyme deficiency 22.93 21.66 4 8411 32 63480575
Bradyphrenia 22.29 21.66 13 8402 6967 63473640
Seizure 22.04 21.66 52 8363 132582 63348025

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 325.63 17.78 143 10865 17791 34928132
Emotional poverty 163.93 17.78 38 10970 560 34945363
Psychotic disorder 156.81 17.78 97 10911 24355 34921568
Extrapyramidal disorder 153.96 17.78 77 10931 12803 34933120
Delusion of grandeur 116.03 17.78 33 10975 1127 34944796
Catatonia 114.06 17.78 47 10961 4978 34940945
Decreased eye contact 102.12 17.78 25 10983 470 34945453
Oppositional defiant disorder 99.55 17.78 25 10983 524 34945399
Psychomotor hyperactivity 98.96 17.78 52 10956 9570 34936353
Aggression 93.98 17.78 86 10922 38878 34907045
Sedation 90.30 17.78 65 10943 20941 34924982
Hallucination, auditory 85.93 17.78 51 10957 11866 34934057
Suicide attempt 84.09 17.78 81 10927 39035 34906888
Bruxism 82.81 17.78 28 10980 1707 34944216
Affective disorder 79.77 17.78 35 10973 4325 34941598
Tardive dyskinesia 79.29 17.78 38 10970 5752 34940171
Homicidal ideation 74.43 17.78 29 10979 2653 34943270
Neutrophil count increased 71.28 17.78 52 10956 17094 34928829
Rhinalgia 70.64 17.78 22 10986 1031 34944892
Foetal disorder 67.13 17.78 20 10988 806 34945117
Parkinsonism 67.09 17.78 38 10970 8100 34937823
Drug withdrawal syndrome neonatal 59.63 17.78 27 10981 3592 34942331
Foetal exposure during pregnancy 58.66 17.78 66 10942 38035 34907888
Neutropenia neonatal 56.82 17.78 17 10991 695 34945228
Dyskinesia 55.04 17.78 50 10958 22363 34923560
Lymphocyte count abnormal 51.97 17.78 18 10990 1180 34944743
Priapism 51.37 17.78 27 10981 4967 34940956
Intentional self-injury 51.05 17.78 39 10969 13732 34932191
Choreoathetosis 46.20 17.78 16 10992 1048 34944875
Trismus 45.54 17.78 20 10988 2475 34943448
Overdose 45.29 17.78 93 10915 90966 34854957
Hyperkinesia 45.14 17.78 18 10990 1750 34944173
Salivary hypersecretion 44.75 17.78 30 10978 8614 34937309
Schizophrenia 44.68 17.78 30 10978 8636 34937287
Crying 44.65 17.78 26 10982 5836 34940087
Sopor 44.18 17.78 34 10974 12102 34933821
Dystonia 43.05 17.78 32 10976 10813 34935110
Arthralgia 39.28 17.78 4 11004 170037 34775886
Agitation 38.97 17.78 67 10941 57332 34888591
Neutropenia 38.90 17.78 123 10885 156655 34789268
Irritability 38.37 17.78 43 10965 24647 34921276
Coordination abnormal 38.30 17.78 26 10982 7618 34938305
Nasal discomfort 36.17 17.78 15 10993 1613 34944310
Congenital cerebrovascular anomaly 35.80 17.78 6 11002 12 34945911
Suicidal ideation 35.44 17.78 53 10955 40335 34905588
Dextrocardia 34.75 17.78 8 11000 114 34945809
SARS-CoV-2 test positive 34.14 17.78 22 10986 5911 34940012
Speech disorder 33.69 17.78 41 10967 25645 34920278
Antisocial personality disorder 33.55 17.78 7 11001 61 34945862
Cerebral amyloid angiopathy 33.54 17.78 8 11000 134 34945789
Foetal alcohol syndrome 33.38 17.78 8 11000 137 34945786
Dyspnoea 33.30 17.78 42 10966 376740 34569183
Blood creatine phosphokinase increased 32.61 17.78 54 10954 44803 34901120
Affect lability 32.53 17.78 18 10990 3665 34942258
Seizure 32.41 17.78 89 10919 104768 34841155
Therapy non-responder 32.40 17.78 50 10958 39096 34906827
Lymphocyte count decreased 31.12 17.78 37 10971 22585 34923338
Poor feeding infant 30.97 17.78 10 10998 527 34945396
Insomnia 30.93 17.78 87 10921 103820 34842103
Pain 30.76 17.78 13 10995 204662 34741261
Drug resistance 30.20 17.78 39 10969 25888 34920035
Premature baby 30.18 17.78 34 10974 19599 34926324
Intestinal obstruction 29.23 17.78 36 10972 22786 34923137
Pain in extremity 29.14 17.78 3 11005 126510 34819413
Treatment noncompliance 27.74 17.78 39 10969 28061 34917862
Streptococcal infection 27.57 17.78 18 10990 4943 34940980
Leukopenia 27.53 17.78 61 10947 62795 34883128
Somnolence 27.36 17.78 87 10921 111029 34834894
Floppy iris syndrome 27.17 17.78 8 11000 309 34945614
Myocarditis 26.88 17.78 27 10981 13655 34932268
Tachycardia 26.23 17.78 72 10936 84700 34861223
Mood altered 26.04 17.78 22 10986 8930 34936993
Depressed mood 25.60 17.78 31 10977 19286 34926637
Spasmodic dysphonia 25.07 17.78 7 11001 223 34945700
Drug withdrawal syndrome 24.94 17.78 31 10977 19803 34926120
Respiratory depression 24.74 17.78 28 10980 16217 34929706
Antipsychotic drug level increased 23.90 17.78 15 10993 3850 34942073
Hiccups 23.78 17.78 22 10986 10060 34935863
Mental impairment 23.34 17.78 22 10986 10300 34935623
Electrocardiogram QT prolonged 22.94 17.78 44 10964 40908 34905015
Mania 22.91 17.78 21 10987 9490 34936433
Long QT syndrome 22.86 17.78 13 10995 2790 34943133
Sleep disorder 22.83 17.78 38 10970 31650 34914273
Treatment failure 22.37 17.78 47 10961 46650 34899273
Pneumonia aspiration 22.23 17.78 44 10964 41859 34904064
Drug interaction 22.16 17.78 134 10874 225812 34720111
Low birth weight baby 22.12 17.78 19 10989 7886 34938037
Acanthosis nigricans 22.00 17.78 6 11002 175 34945748
Agranulocytosis 21.95 17.78 32 10976 23789 34922134
Faecaloma 21.64 17.78 16 10992 5361 34940562
Portal tract inflammation 21.42 17.78 5 11003 76 34945847
Poor quality sleep 21.40 17.78 19 10989 8237 34937686
Pruritus 21.34 17.78 9 10999 141972 34803951
Neuroblastoma 21.29 17.78 6 11002 198 34945725
Faecal vomiting 20.57 17.78 7 11001 435 34945488
Drug screen false positive 20.54 17.78 8 11000 731 34945192
Toxicity to various agents 19.74 17.78 119 10889 200243 34745680
Delirium 19.60 17.78 43 10965 43948 34901975
Electroconvulsive therapy 19.59 17.78 4 11004 31 34945892
Unmasking of previously unidentified disease 18.89 17.78 8 11000 906 34945017
Pulmonary valve incompetence 18.85 17.78 8 11000 911 34945012
Intentional overdose 18.68 17.78 42 10966 43632 34902291
Incorrect dose administered 18.50 17.78 40 10968 40475 34905448
Poisoning deliberate 18.27 17.78 17 10991 7827 34938096
Drug abuse 17.83 17.78 70 10938 99026 34846897

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 557.23 17.68 214 17223 27345 79699606
Catatonia 239.53 17.68 85 17352 8671 79718280
Sopor 222.08 17.68 119 17318 32891 79694060
Extrapyramidal disorder 190.70 17.68 95 17342 22584 79704367
Psychotic disorder 189.24 17.68 116 17321 41286 79685665
Aggression 176.69 17.68 120 17317 50838 79676113
Suicide attempt 175.04 17.68 145 17292 82787 79644164
Psychomotor hyperactivity 160.90 17.68 77 17360 16772 79710179
Overdose 150.36 17.68 193 17244 184013 79542938
Drug abuse 149.65 17.68 181 17256 162510 79564441
Emotional poverty 147.07 17.68 35 17402 852 79726099
Toxicity to various agents 143.89 17.68 297 17140 421243 79305708
Tardive dyskinesia 141.06 17.68 61 17376 10510 79716441
Sedation 131.38 17.68 101 17336 51794 79675157
Hallucination, auditory 129.12 17.68 71 17366 20622 79706329
Delusion of grandeur 121.05 17.68 33 17404 1399 79725552
Intentional self-injury 118.70 17.68 79 17358 32340 79694611
Oppositional defiant disorder 111.08 17.68 25 17412 472 79726479
Electrocardiogram QT prolonged 104.03 17.68 113 17324 90273 79636678
Agitation 103.33 17.68 118 17319 99597 79627354
Decreased eye contact 102.22 17.68 26 17411 839 79726112
Salivary hypersecretion 86.52 17.68 48 17389 14176 79712775
Coma 82.85 17.68 106 17331 100543 79626408
Arthralgia 76.48 17.68 16 17421 571787 79155164
Somnolence 76.19 17.68 164 17273 238817 79488134
Intentional overdose 75.52 17.68 104 17333 105856 79621095
Pain 75.29 17.68 30 17407 703772 79023179
Homicidal ideation 73.91 17.68 28 17409 3429 79723522
Mania 70.48 17.68 46 17391 18214 79708737
Affective disorder 70.35 17.68 35 17402 8284 79718667
Bruxism 69.77 17.68 28 17409 3998 79722953
Neutrophil count increased 69.56 17.68 55 17382 29341 79697610
Parkinsonism 69.50 17.68 44 17393 16540 79710411
Pneumonia aspiration 68.92 17.68 79 17358 66888 79660063
Drug interaction 66.00 17.68 220 17217 414963 79311988
Completed suicide 65.37 17.68 157 17280 245610 79481341
Blood creatine phosphokinase increased 64.72 17.68 76 17361 66014 79660937
Poisoning deliberate 64.40 17.68 44 17393 18784 79708167
Dyskinesia 62.31 17.68 62 17375 44711 79682240
Dyspnoea 61.86 17.68 58 17379 856967 78869984
Rhinalgia 61.02 17.68 22 17415 2345 79724606
Priapism 60.11 17.68 26 17411 4479 79722472
Seizure 58.33 17.68 128 17309 188706 79538245
Dystonia 57.10 17.68 43 17394 21356 79705595
Pain in extremity 55.84 17.68 7 17430 364531 79362420
Lymphocyte count abnormal 54.39 17.68 18 17419 1485 79725466
Tachycardia 50.97 17.68 117 17320 177651 79549300
Choreoathetosis 49.69 17.68 17 17420 1553 79725398
Altered state of consciousness 49.01 17.68 54 17383 43768 79683183
Muscle rigidity 48.76 17.68 38 17399 19844 79707107
Joint swelling 48.18 17.68 4 17433 288642 79438309
Myocarditis 47.88 17.68 39 17398 21694 79705257
Delusion 47.86 17.68 38 17399 20385 79706566
Respiratory depression 45.52 17.68 42 17395 27588 79699363
Hyperkinesia 43.93 17.68 18 17419 2711 79724240
Trismus 43.28 17.68 22 17415 5445 79721506
Mutism 42.85 17.68 17 17420 2355 79724596
Depressed level of consciousness 41.21 17.68 75 17362 96577 79630374
Suicidal ideation 38.77 17.68 64 17373 76276 79650675
Delirium 37.78 17.68 67 17370 84560 79642391
Treatment noncompliance 36.75 17.68 51 17386 52217 79674734
Neutropenia 36.69 17.68 142 17295 287568 79439383
Infusion related reaction 36.28 17.68 4 17433 230233 79496718
Lymphocyte count decreased 36.07 17.68 48 17389 47241 79679710
Antipsychotic drug level increased 35.94 17.68 20 17417 5937 79721014
Hallucinations, mixed 35.82 17.68 21 17416 6878 79720073
Mental disorder 35.74 17.68 39 17398 31263 79695688
Hypersensitivity 35.69 17.68 7 17430 262232 79464719
Antisocial personality disorder 35.51 17.68 7 17430 67 79726884
Affect lability 35.43 17.68 25 17412 11234 79715717
Psychomotor retardation 35.24 17.68 20 17417 6164 79720787
Torsade de pointes 35.04 17.68 31 17406 19281 79707670
Irritability 34.88 17.68 44 17393 41100 79685851
Leukopenia 33.72 17.68 77 17360 116436 79610515
Grandiosity 33.69 17.68 10 17427 577 79726374
Peripheral swelling 33.11 17.68 9 17428 269608 79457343
Mood altered 33.09 17.68 29 17408 17818 79709133
Stereotypy 32.93 17.68 11 17426 934 79726017
Headache 32.84 17.68 58 17379 653714 79073237
Schizophrenia 32.53 17.68 27 17410 15413 79711538
Coordination abnormal 31.83 17.68 28 17409 17284 79709667
Agranulocytosis 31.75 17.68 44 17393 44986 79681965
Pruritus 31.69 17.68 24 17413 394624 79332327
Congenital cerebrovascular anomaly 31.65 17.68 5 17432 10 79726941
Abdominal discomfort 31.49 17.68 8 17429 250719 79476232
Swelling 31.19 17.68 5 17432 216706 79510245
Abnormal behaviour 30.95 17.68 39 17398 36382 79690569
Drug resistance 30.90 17.68 42 17395 42171 79684780
Speech disorder 30.87 17.68 48 17389 54397 79672554
Schizoaffective disorder 30.62 17.68 13 17424 2139 79724812
Cerebral amyloid angiopathy 29.34 17.68 8 17429 339 79726612
Hepatic enzyme increased 29.20 17.68 3 17434 182607 79544344
Confusional state 29.08 17.68 142 17295 317855 79409096
Floppy iris syndrome 28.99 17.68 8 17429 355 79726596
Lactate pyruvate ratio increased 28.68 17.68 6 17431 79 79726872
Drug intolerance 28.57 17.68 11 17426 264108 79462843
Rhabdomyolysis 28.57 17.68 67 17370 103064 79623887
SARS-CoV-2 test positive 27.88 17.68 22 17415 11694 79715257
Back pain 27.79 17.68 16 17421 304164 79422787
Intentional product misuse 27.65 17.68 63 17374 95102 79631849
Akathisia 27.55 17.68 23 17414 13236 79713715
Bradyphrenia 27.54 17.68 21 17416 10619 79716332
Disorganised speech 27.53 17.68 12 17425 2105 79724846
Electroconvulsive therapy 27.31 17.68 6 17431 101 79726850
Hepatocellular injury 27.03 17.68 42 17395 47551 79679400
Crying 26.81 17.68 29 17408 23014 79703937
Rash 26.66 17.68 54 17383 578304 79148647
Epileptic encephalopathy 26.52 17.68 8 17429 488 79726463
Wrong patient received product 26.49 17.68 15 17422 4603 79722348
Restlessness 26.37 17.68 41 17396 46451 79680500
Hyperprolactinaemia 26.32 17.68 15 17422 4661 79722290
Spasmodic dysphonia 26.29 17.68 7 17430 271 79726680
Blood folate decreased 25.97 17.68 10 17427 1279 79725672
Encephalopathy 25.86 17.68 50 17387 67347 79659604
Cardiac arrest 25.32 17.68 89 17348 172007 79554944
Behaviour disorder 24.59 17.68 16 17421 6297 79720654
Blood citric acid increased 24.41 17.68 5 17432 59 79726892
Cardio-respiratory arrest 24.28 17.68 65 17372 108445 79618506
Streptococcal infection 24.12 17.68 18 17419 8812 79718139
Nasal discomfort 24.10 17.68 15 17422 5468 79721483
Cough 23.89 17.68 27 17410 366762 79360189
Incorrect dose administered 23.68 17.68 52 17385 76578 79650373
Acanthosis nigricans 23.46 17.68 6 17431 198 79726753
Tremor 23.35 17.68 86 17351 169997 79556954
Hypertension 23.08 17.68 23 17414 330969 79395982
Long QT syndrome 22.97 17.68 15 17422 5940 79721011
Hepatic cytolysis 22.95 17.68 29 17408 27122 79699829
Eosinophilic myocarditis 22.92 17.68 9 17428 1213 79725738
Drug-induced liver injury 22.90 17.68 47 17390 66070 79660881
Myoclonus 22.52 17.68 29 17408 27631 79699320
Nasopharyngitis 22.28 17.68 14 17423 253867 79473084
Miosis 22.21 17.68 22 17415 15767 79711184
Onychophagia 21.71 17.68 5 17432 105 79726846
Abortion 21.68 17.68 9 17428 1401 79725550
Status epilepticus 21.57 17.68 27 17410 25014 79701937
Anticholinergic syndrome 21.45 17.68 12 17425 3599 79723352
Parkinsonian gait 21.43 17.68 8 17429 940 79726011
Sinusitis 21.38 17.68 8 17429 195493 79531458
Fatigue 21.32 17.68 118 17319 929609 78797342
Dysarthria 21.02 17.68 46 17391 67576 79659375
Hallucination 20.86 17.68 53 17384 85692 79641259
Portal tract inflammation 20.84 17.68 5 17432 126 79726825
Drug screen false positive 20.21 17.68 8 17429 1101 79725850
Withdrawal syndrome 20.08 17.68 27 17410 26827 79700124
Torticollis 20.05 17.68 10 17427 2377 79724574
Faecaloma 19.86 17.68 18 17419 11546 79715405
Illusion 19.85 17.68 9 17428 1732 79725219
Poisoning 19.80 17.68 26 17411 25246 79701705
Echolalia 19.73 17.68 6 17431 376 79726575
Myalgia 19.63 17.68 8 17429 185633 79541318
Depressed mood 18.63 17.68 36 17401 48444 79678507
Influenza 18.62 17.68 3 17434 129603 79597348
Psychiatric symptom 18.46 17.68 14 17423 7021 79719930
Unmasking of previously unidentified disease 18.42 17.68 9 17428 2048 79724903
Chest discomfort 18.12 17.68 4 17433 138040 79588911
Persecutory delusion 18.05 17.68 12 17425 4897 79722054
Urticaria 17.99 17.68 9 17428 185192 79541759
Gaze palsy 17.89 17.68 10 17427 2995 79723956

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AA01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with aliphatic side-chain
FDA CS M0016525 Phenothiazines
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drugs
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:76779 post-proline endopeptidase inhibitors
CHEBI has role CHEBI:149553 anticoronaviral drug
MeSH PA D000932 Antiemetics
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA EPC N0000175746 Phenothiazine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nausea and vomiting indication 16932000
Disruptive behavior disorder indication 54319003
Schizophrenia indication 58214004 DOID:5419
Psychotic disorder indication 69322001
Bipolar affective disorder, current episode manic indication 191618007
Acute intermittent porphyria indication 234422006 DOID:3890
Pre-Op Apprehension indication
Tetanus Adjunct Treatment indication
Intractable Hiccups indication
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.04 Basic
pKa2 2.21 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.15 WOMBAT-PK CHEMBL
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.54 WOMBAT-PK
Mu-type opioid receptor GPCR Ki 5.23 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 7.19 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 6.20 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.72 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.83 WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 6.22 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 6.92 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 7.72 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 6.17 CHEMBL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.10 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 7.28 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 7.40 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.44 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 7.41 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 9.55 PDSP
D(1B) dopamine receptor GPCR Ki 6.93 WOMBAT-PK
Histamine H1 receptor GPCR Ki 8.20 WOMBAT-PK
Histamine H2 receptor GPCR Ki 6.76 PDSP
Histamine H4 receptor GPCR Ki 6.87 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 7.60 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 6.75 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 7.25 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 7.40 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 7.38 PDSP
Aldehyde oxidase Enzyme IC50 6.24 WOMBAT-PK
5-hydroxytryptamine receptor 1B GPCR Ki 5.83 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 6.35 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.10 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.68 DRUG MATRIX
Cytochrome P450 2D6 Enzyme Ki 5.16 WOMBAT-PK
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.69 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 8.71 DRUG MATRIX
5-hydroxytryptamine receptor 3A Ion channel Ki 6.01 PDSP
Alpha-1B adrenergic receptor GPCR Ki 9.09 PDSP
Kappa-type opioid receptor GPCR Ki 5.35 DRUG MATRIX
Calmodulin Cytosolic other Kd 5.91 CHEMBL
Delta-type opioid receptor GPCR Ki 5.13 DRUG MATRIX
5-hydroxytryptamine receptor 5A GPCR Ki 6.93 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 6.46 PDSP
Epidermal growth factor receptor Kinase IC50 4.54 DRUG MATRIX
Potassium channel subfamily K member 2 Ion channel IC50 5.57 CHEMBL
Tyrosine-protein kinase Fyn Kinase IC50 5.06 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 4.71 DRUG MATRIX
Ryanodine receptor 1 Ion channel IC50 3.57 WOMBAT-PK
Major prion protein Surface antigen EC50 5.70 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.57 CHEMBL
Substance-K receptor GPCR Ki 5.04 DRUG MATRIX
Melanocortin receptor 4 GPCR Ki 4.84 DRUG MATRIX
Melanocortin receptor 5 GPCR Ki 5.15 DRUG MATRIX
Melanocortin receptor 3 GPCR Ki 4.67 DRUG MATRIX
Solute carrier family 22 member 2 Transporter IC50 4.85 WOMBAT-PK
Glutamate [NMDA] receptor Ion channel IC50 6.22 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.37 CHEMBL
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 5.99 CHEMBL
Sphingomyelin phosphodiesterase Enzyme IC50 4.96 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 7.60 WOMBAT-PK
Trypanothione reductase Enzyme Ki 5.49 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 4.80 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 8.31 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.74 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.78 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 8.07 CHEMBL
Histamine H1 receptor GPCR Ki 7.30 CHEMBL
D(2) dopamine receptor GPCR Ki 8.92 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.75 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 7.68 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 5.30 IUPHAR
D(1A) dopamine receptor GPCR Ki 7.46 CHEMBL
D(2) dopamine receptor GPCR IC50 7.10 CHEMBL
Transient receptor potential cation channel subfamily V member 1 Ion channel Ki 5.89 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 8.40 IUPHAR
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.35 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 5.89 CHEMBL
Glutamate NMDA receptor Ion channel IC50 5.89 CHEMBL
Muscarinic acetylcholine receptor GPCR Ki 7.22 CHEMBL
Dopamine receptor GPCR IC50 7.60 CHEMBL
Dopamine receptor GPCR Ki 7.85 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 9.15 CHEMBL
Adenylate cyclase Enzyme Ki 6.93 CHEMBL
Calmodulin Cytosolic other IC50 5.60 CHEMBL
Major prion protein Unclassified EC50 5.70 CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Enzyme IC50 4.64 CHEMBL

External reference:

IDSource
4017861 VUID
N0000146214 NUI
D00270 KEGG_DRUG
69-09-0 SECONDARY_CAS_RN
104728 RXNORM
4017860 VANDF
4017861 VANDF
C0008286 UMLSCUI
CHEBI:3647 CHEBI
Z80 PDB_CHEM_ID
CHEMBL71 ChEMBL_ID
CHEMBL1713 ChEMBL_ID
DB00477 DRUGBANK_ID
D002746 MESH_DESCRIPTOR_UI
2726 PUBCHEM_CID
83 IUPHAR_LIGAND_ID
183 INN_ID
U42B7VYA4P UNII
2140 MMSL
4264 MMSL
4428 MMSL
4429 MMSL
71853 MMSL
d00064 MMSL
001470 NDDF
004587 NDDF
387258005 SNOMEDCT_US
387479008 SNOMEDCT_US
47331002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9836 INJECTION 25 mg INTRAMUSCULAR ANDA 12 sections
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9836 INJECTION 25 mg INTRAMUSCULAR ANDA 12 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2961 TABLET, COATED 10 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2961 TABLET, COATED 10 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2962 TABLET, COATED 25 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2962 TABLET, COATED 25 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2963 TABLET, COATED 50 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2963 TABLET, COATED 50 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2964 TABLET, COATED 100 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2964 TABLET, COATED 100 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2965 TABLET, COATED 200 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2965 TABLET, COATED 200 mg ORAL ANDA 14 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-1397 INJECTION 25 mg INTRAMUSCULAR ANDA 17 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-1398 INJECTION 25 mg INTRAMUSCULAR ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-4027 CONCENTRATE 30 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-4028 CONCENTRATE 100 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5913 TABLET, SUGAR COATED 10 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5914 TABLET, SUGAR COATED 25 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5915 TABLET, SUGAR COATED 50 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5916 TABLET, SUGAR COATED 100 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5917 TABLET, SUGAR COATED 200 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0300 TABLET, SUGAR COATED 10 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0300 TABLET, SUGAR COATED 10 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0301 TABLET, SUGAR COATED 25 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0301 TABLET, SUGAR COATED 25 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0302 TABLET, SUGAR COATED 50 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0302 TABLET, SUGAR COATED 50 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0303 TABLET, SUGAR COATED 100 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0303 TABLET, SUGAR COATED 100 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0304 TABLET, SUGAR COATED 200 mg ORAL ANDA 14 sections